Le Lézard
Classified in: Health
Subject: PLW

Argentum Pharmaceuticals Succeeds in Starting Patent Cancellation Trial Against Novartis' AFINITOR®


NEW YORK, Sept. 29, 2017 /PRNewswire/ -- The U.S. Patent & Trademark Office (PTO) on September 25, 2017 granted Argentum Pharmaceuticals LLC's petition for inter partes review (IPR) against all claims of the last-expiring patent listed as covering Novartis Pharmaceuticals' AFINITOR® (everolimus tablet) drug in the Food & Drug Administration's Orange Book.  Argentum challenges claims 1?3 of Novartis' U.S. Patent No. 9,006,224, which the Orange Book states will expire in 2028.  The PTO concluded that Argentum has established a "reasonable likelihood that [Argentum] would prevail with respect to claims 1?3" of the patent.  The decision marks the beginning of an IPR trial that will be conducted by three specialist patent judges within the PTO's Patent Trial & Appeal Board.  A final decision on patentability in the IPR is due within 1 year.

Argentum Pharmaceuticals. Balancing the rights of pharmaceutical innovators and consumers. (PRNewsFoto/Argentum Pharmaceuticals)

About Argentum Pharmaceuticals

Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.  http://www.argentumpharmaceuticals.com

SOURCE Argentum Pharmaceuticals


These press releases may also interest you

at 17:05
Sirona Biochem Corp. ("Sirona") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in...

at 17:00
The Doctors Company, the nation's largest physician-owned medical malpractice insurer, announced today that it has approved a 2024 premium dividend of approximately $14.7 million, bringing the total of declared dividends to date to $470 million....

at 17:00
Northern Virginia Oral, Maxillofacial & Implant Surgery ("NOVA OMS") has learned of a data security incident that may have impacted data belonging to certain patients and guarantors. On October 5, 2023, NOVA OMS became aware of unusual activity on...

at 17:00
The Journey Venture Studio announced today a strategic collaboration with Valleywise Health, a comprehensive healthcare system with locations throughout the Phoenix metro area. In pursuit of fostering innovation, this collaboration is set to...

at 16:32
The wishes that Make-A-Wish grants wouldn't be possible without the support of countless "WishMakers" such as donors, volunteers, corporate partners, community advocates and more. "WishMakers" ? a term for anyone who steps up to take action...

at 16:30
Today, the Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, announced a new appointment to the Canadian Centre on Substance Use and Addiction (CCSA) Board of Directors. Scott Elliott is appointed as...



News published on and distributed by: